IRE ELiT

Unlike radiochemical production, IRE ELiT's radiopharmaceutical products can be administered directly to patients thanks toan additional sterilisation phase. At the current stage, the radiopharmaceutical activities are aimed at the production of Y-90 and W-188/Re-188 generators. The most recent developmentsin the use of Re-188 relate to cancer therapy, palliative care for bone pain caused by spreading of breast and prostate cancer, the treatment of synovitis and cardiology. Y-90 effectively fights certain lymphomas, liver cancers & cancers from the immune system.

IRE ELiT, because of the nature of the product, is directly dealing with distributors and users of the product, including oncologist, nuclear medicine specialists and other pathology specialist (endocrinologist, hepatologist...).IRE ELiT is targeting the mature markets (Europe, North-America and Japan) as well as the emerging countries market in Asia and South-America.